Floctafenine|CAS 23779-99-9|DC Chemicals

Cas No.:	23779-99-9
Chemical Name:	Floctafenine
Synonyms:	2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)quinolin-4-yl)amino)benzoate;Floctafenine;2,3-Dihydroxypropyl 2-((8-(trifluoromethyl)-quinolin-4-yl)amino)benzoate;2,3-dihydroxypropyl 2-[[8-(trifluoromethyl)quinolin-4-yl]amino]benzoate;Benzoic acid,2-[[8-(trifluoromethyl)-4-quinolinyl]amino]-, 2,3-dihydroxypropyl ester;4-[o-(2',3'-dihydroxypropyloxycarbonyl)-phenyl]-amino-8-trifluoromethyl-quinoline;Diralgan;Floctafenina [INN-Spanish];Floctafeninum [INN-Latin];Idalon;Idarac;Novodolan;R 4318;2,3-Dihydroxypropyl N-[8-(trifluoromethyl)-4-quinolyl]anthranilate;RU 15750;NCGC00249912-01;FLOCTAFENINE [USAN];R-4138;EINECS 245-881-4;DB08976;Floctafenine [USAN:INN:BAN:JAN];DTXCID9031484;Idarac (TN);A878143;UNII-O04HVX6A9Q;FLOCTAFENINE [MART.];Floctafenina;FLOCTAFENIN;2, 3-dihydroxypropyl 2-[[8-(trifluoromethyl)quinolin-4-yl]amino]benzoate;BRN 0457808;23779-99-9;SB73211;O04HVX6A9Q;CHEBI:31612;4-(o-(2',3'-Dihydroxypropyloxycarbonyl)phenyl)-amino-8-trifluoromethylquinoline;FLOCTAFENINE [JAN];CAS-23779-99-9;FT-0668555;D01267;SCHEMBL26841;FLOCTAFENINE [MI];EN300-19765892;2-(8'-Trifluoromethyl-4'-quinolylamino)benzoic acid 2,3-dihydroxy propyl ester;FLOCTAFENINE [WHO-DD];2,3-dihydroxypropyl 2-{[8-(trifluoromethyl)quinolin-4-yl]amino}benzoate;2,3-Dihydroxypropyl N-(8-(trifluoromethyl)-4-quinolyl)anthranilate;8-Trifluoromethyl-7-deschloroglafenine;CS-0017604;Ru-15750;Benzoic acid, 2-[[8-(trifluoromethyl)-4-quinolinyl]amino]-, 2,3-dihydroxypropyl ester;Floctafeninum;Tox21_113688;Floctafenine (JAN/USAN/INN);R-4318;AKOS015998661;NS00006030;Benzoic acid, 2-((8-(trifluoromethyl)-4-quinolinyl)amino)-, 2,3-dihydroxypropyl ester;Duralgin;FLOCTAFENINE [INN];Benzoic acid, 2-(8'-trifluoromethyl-4'-quinolylamino)-, 2,3-dihydroxypropyl ester;HY-A0259;Q5459971;DTXSID8057695;CHEMBL2105075;BRD-A23418262-001-01-5;DA-73380;G85831
SMILES:	C1=CC=C(C(=C1)C(=O)OCC(CO)O)NC2=CC=NC3=C2C=CC=C3C(F)(F)F
Formula:	C₂₀H₁₇N₂O₄F₃
M.Wt:	406.35518
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.